DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves midday: Nvidia, Boeing, Live Nation Entertainment and more
▼ + stars: | 2024-05-23 | by ( Sarah Min | ) www.cnbc.com time to read: +3 min

Nvidia — The chipmaker and artificial intelligence beneficiary spiked 11% after Nvidia posted strong fiscal first-quarter results , issued better-than-expected guidance and announced a 10-for-1 stock split. Live Nation Entertainment — Shares dropped 7% after the U.S. Department of Justice sued to break up the parent company of Ticketmaster, alleging antitrust violations . The cosmetics maker posted fourth-quarter adjusted earnings of 53 cents per share on revenues of $321.1 million. Snowflake had posted $829 million in revenue, surpassing the consensus forecast of $786 million, per LSEG. Adjusted earnings for the period came in at 14 cents a share, however, falling short of analysts' consensus estimate by 4 cents.

Persons: Brian West, LSEG, LiveRamp, GoodRx, Snowflake, Goldman Sachs, Morgan Stanley, — CNBC's Michelle Fox, Pia Singh Organizations: Nvidia, Micro Computer, Boeing —, Boeing, U.S . Department of Justice, Ticketmaster, RBC, Taiwan Semiconductor Manufacturing, Taiwan Semiconductor, Machinery, Titan Machinery, Triumph, JPMorgan, Corp, LSEG, Revenue

☆ Stocks making the biggest moves before the bell: NVDA, LYV, SNOW
▼ + stars: | 2024-05-23 | by ( Alex Harring | ) www.cnbc.com time to read: +4 min

Snowflake posted $829 million in revenue, while analysts polled by LSEG had called for $786 million. Adjusted earnings for the period came in at 14 cents a share, however, missing the consensus estimate by 4 cents. Beauty — The cosmetics maker added 3.4% after easily surpassing consensus forecasts from analysts surveyed by FactSet for the fiscal fourth quarter. posted 53 cents in earnings per share, excluding items, on $321.1 million in revenue, while analysts penciled in just 33 cents on $292.6 million in revenue. On top of that, LiveRamp offered firm revenue guidance for both the current quarter and full year.

Persons: Snowflake, LSEG, NetEase, FactSet, e.l.f, LiveRamp, Cytokinetics, Goldman Sachs, Morgan Stanley, Ed Bred, Lori Koch, Alibaba, GoodRX, —, Jesse Pound, Pia Singh, Yun Li, Tanaya Macheel, Sarah Min, Michelle Fox Organizations: Nvidia, Micro, Taiwan Semiconductor, Bloomberg, Department of Justice, of, News, Corp, JPMorgan, DuPont de Nemours, DuPont, Bloomberg News, Bank of America, RBC, Hasbro —, Hasbro Locations: Southern, of New York, —

☆ Stocks making the biggest moves after hours: Nvidia, Snowflake, VF Corp. and more
▼ + stars: | 2024-05-22 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

Check out the companies making headlines after the bell : Nvidia — The chipmaker added about 4% after announcing a 10-for-1 stock split . Nvidia also surpassed Wall Street's fiscal first-quarter estimates on the top and bottom lines, and it issued strong guidance for the current quarter. Fiscal first-quarter revenue surpassed the Street's expectations, coming in at $829 million, versus consensus estimates for $786 million, per LSEG. — The apparel and footwear company sank 9% after posting an unexpected loss for the recent quarter and revenue that fell short of Wall Street's estimates. VF Corp. posted a loss of 32 cents per share on $2.37 billion in revenue.

Persons: LSEG, FactSet, Synopsys, LiveRamp, Dow Jones, Goldman Sachs, Morgan Stanley, Ed Breen, Lori Koch, Breen, —, Darla Mercado, Sarah Min, Scott Schnipper, Christina Cheddar, Berk Organizations: Nvidia, Super Micro, Devices, Corp, VF Corp, LiveRamp Holdings, News Corp, JPMorgan, DuPont de Nemours, DuPont

☆ These are JPMorgan's top stocks for February
▼ + stars: | 2024-02-06 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

Stocks are coming off a winning month, with the three major indexes finishing January up by more than 1%. CNBC Pro compiled 10 of the stocks on his list, including four new names: Cars.com , Insulet , Intuitive Surgical and Prologis . More than seven out of every 10 analysts rate the stock a buy, according to FactSet. The average price target implies the stock can rally more than 27% in the next 12 months. More than four out of every five analysts rate the stock a buy, with an average price target showing upside of more than 13%.

Persons: Stocks, Cars.com, Mizuho Organizations: JPMorgan, Federal Reserve, Investors, CNBC, Vertex Pharmaceuticals Locations: Dexcom

☆ Here are JPMorgan’s top stock picks heading into December
▼ + stars: | 2023-12-01 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

JPMorgan Chase added a key information security stock to its list of favorite stock picks for December and parted with three names, including HP , from November . The firm added CyberArk to its Analyst Focus List, as well as biopharmaceutical firm Cytokinetics . The JPMorgan list covers its best stock ideas that fit into three categories: growth, value and short investment ideas. Here are some of the other top picks on the JPMorgan list. CYBR YTD mountain CyberArk stock.

Persons: JPMorgan Chase, Nicholas Rosato Jr, Rosato, — CNBC's Michael Bloom Organizations: JPMorgan, HP, Palo Alto Networks, North

☆ Here are Thursday's biggest analyst calls: Nvidia, Disney, Tesla, Instacart, Arm, Rivian, Target & more
▼ + stars: | 2023-11-09 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Thursday's biggest calls on Wall Street: Goldman Sachs initiates Apellis Pharmaceuticals as buy Goldman initiated the biotech company with a buy and says it sees "continued execution." Bank of America reiterates Disney as buy Bank of America said it's standing by its buy rating after Wednesday's earnings report. Goldman Sachs reiterates Arm as overweight Goldman said it's sticking with its buy rating after the stock's earnings report on Wednesday. Goldman Sachs reiterates Instacart as buy Goldman said it's sticking with its buy rating on the grocery delivery company after Instacart's earnings report on Wednesday. Morgan Stanley reiterates Rivian as overweight Morgan Stanley said it's sticking with its overweight rating on the electric vehicle company. "

Persons: Goldman Sachs, Goldman, Tesla, WK Kellogg, Kellogg, Wolfe, Instacart, Morgan Stanley, Rivian, Eli Lilly, MRK's Keytruda, Evercore, it's bullish, Parker, Wells, it's, Hein Schumacher Organizations: Apellis Pharmaceuticals, HSBC, Tesla, Barclays, JPMorgan, Bank of America, Disney, ARM, Deutsche Bank, Deutsche, Merck, pharma, TAP, Industrial, Nvidia, Anheuser, Busch InBev, Bud, Offshore, Unilever, OW, Citi Locations: North America, Montrose

☆ Cytokinetics will seek international approval for drug following FDA rejection, says CEO Robert Blum
▼ + stars: | 2023-03-01 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCytokinetics will seek international approval for drug following FDA rejection, says CEO Robert BlumCytokinetics President and CEO Robert Blum joins 'Power Lunch' to discuss the FDA's rejection of the company's heart failure drug, how FDA approval increases shareholder value and future treatment plans up for FDA approval.

☆ U.S. FDA declines to approve Cytokinetics' heart drug
▼ + stars: | 2023-02-28 | by ( ) www.reuters.com time to read: 1 min

Feb 28 (Reuters) - Cytokinetics Inc (CYTK.O) said on Tuesday the U.S health regulator declined to approve its oral drug for a type of heart failure, citing lack of sufficient data to show the drug was effective. The U.S. Food and Drug Administration's decision comes after a panel of outside experts in December recommended against allowing the use of the drug due to safety concerns. Reporting by Pratik Jain and Bhanvi Satija in Bengaluru; Editing by Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

☆ Biotech stocks that could surge more than 35% include one name targeting treatments for schizophrenia
▼ + stars: | 2023-02-09 | by ( Sarah Min | ) www.cnbc.com time to read: +3 min

Still, the outlook for biotech stocks could improve now , with innovation in new drugs and more merger and acquisition activity driving investor interest. Recently, Wall Street has been zoning in on developments in treatments for Alzheimer's diseases, drugs for weight loss and treatments using gene editing. CNBC Pro screened for biotech stocks that are part of the iShares Biotechnology ETF , searching for names with huge upside from current prices. In January, Piper Sandler initiated research coverage of Karuna with an overweight rating, saying it's "blazing a new trail in Schizophrenia" treatments. The stock was named another top 2023 pick by Piper Sandler, which said Legend has a "best-in-class" treatment for adults with relapsed multiple myeloma, a segment "with demand far outpacing supply."

☆ Health-care stocks are looking good for 2023 and not just because the sector is a 'safe haven'
▼ + stars: | 2022-12-21 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Investors looking for cover this year would have done well if they sought a safe haven in large-cap pharmaceutical stocks, a trend that is likely to continue into 2023. The Inflation Reduction Act provided some clarity around drug pricing that should help health-care stocks. The average price target, according to FactSet, is $62, or nearly 40% above the stock's closing price on Tuesday. Gene therapies in focus Investors will be closely watching the progress of several gene therapies, according to Phipps. "Yes, these are expensive therapies," Phipps said.

Search resuls for: "Cytokinetics"

10 mentions found